Bristol-Myers Squibb (BMY) named among Best Low Risk Stocks for Retirement Portfolios. Janux Therapeutics partners with BMY on new cancer treatment for solid tumors. Therapy targets common tumor marker across different cancer types. Janux to handle preclinical testing, BMY to lead clinical trials and global commercialization. BMY focuses on developing medicines for serious diseases. No promotional content included in news article.

Read more at Yahoo Finance: Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy